SANDOZ CLOZAPINE TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

CLOZAPINE

Dostupno od:

SANDOZ CANADA INCORPORATED

ATC koda:

N05AH02

INN (International ime):

CLOZAPINE

Doziranje:

100MG

Farmaceutski oblik:

TABLET

Sastav:

CLOZAPINE 100MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

ATYPICAL ANTIPSYCHOTICS

Proizvod sažetak:

Active ingredient group (AIG) number: 0122583002; AHFS:

Status autorizacije:

CANCELLED PRE MARKET

Datum autorizacije:

2022-07-25

Svojstava lijeka

_ _
_Sandoz Clozapine Page 1 of 53_
PRODUCT MONOGRAPH
PR
SANDOZ CLOZAPINE
Clozapine Tablets
25 mg and 100 mg tablets
Antipsychotic Agent
Sandoz Canada Inc.
Date of Revision:
110 rue de Lauzon
March 20, 2020
Boucherville, QC, Canada
J4B 1E6
Control No.: 237094
_ _
_Sandoz Clozapine Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
20
DRUG INTERACTIONS
..................................................................................................
25
DOSAGE AND ADMINISTRATION
..............................................................................
27
OVERDOSAGE
................................................................................................................
30
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 31
STORAGE AND STABILITY
..........................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
33
PHARMACEUTICAL
INFORMATION..........................................................................
33
CLINICAL TRIALS
..........................................................................................................
34
DETAILED PHARMACOLOGY
..................................................